X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Hocena (antroquinonol) inhibits Ras and Ras-related GTP-binding protein activation and is being investigated in combination with the standard of care nab-paclitaxel plus gemcitabine for first-line treatment of metastatic pancreatic cancer.
Lead Product(s): Antroquinonol,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: Hocena
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2023
Details:
Antroquinonol (HOCENA®), an oral investigational small molecule has made headway with COVID-19 treatment development. Phase 2 trial can be extended recruiting hospitalized patients to severe hospitalized COVID-19 patients who need non-invasive oxygen support.
Lead Product(s): Antroquinonol
Therapeutic Area: Infections and Infectious Diseases Product Name: Hocena
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2021
Details:
Antroquinonol® has shown anti-viral, anti-inflammatory and anti-fibrotic characteristics in past animal studies, suggesting high likelihood in becoming successful treatment option for coronavirus-induced pneumonia.
Lead Product(s): Antroquinonol
Therapeutic Area: Infections and Infectious Diseases Product Name: Hocena
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2021
Details:
Antroquinonol outperformed the other listing drugs for the treatment of relapsed acute myeloid leukemia in its Phase 2 clinical trial. 80% of patients showed that their blasts count were less than 5%. 90% of patients did not need blood transfusion during trial period.
Lead Product(s): Antroquinonol
Therapeutic Area: Oncology Product Name: Hocena
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 26, 2020
Details:
The Phase II trial will be a randomized, double-blinded, placebo-controlled study of Antroquinonol as a potential treatment option for mild-to-moderate pneumonia in COVID-19 patients.
Lead Product(s): Antroquinonol
Therapeutic Area: Infections and Infectious Diseases Product Name: Hocena
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
Details:
GBC’s Antroquinonol had been selected in the top 21 candidates of best treating projects in the first round of selection in global solicitation of Covid-19 pneumonia treatment projects.
Lead Product(s): Antroquinonol
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
